Advertisement
Advertisement
NMRA
Neumora Therapeutics, Inc. Common Stock
0.50
USDSponsored
-0.05
-9.11%
Oct 02, 15:59 UTC -4
Closed
After-Market
0.50
0.00
-0.38%
NMRA Earnings Reports
Positive Surprise Ratio
NMRA beat 7 of 12 last estimates.
58%
Next Report
Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q2 26 (Revenue/ EPS)
--
/--
Implied change from Q-- -- (Revenue/ EPS)
--
/--
Neumora Therapeutics, Inc. Common Stock earnings per share and revenue
On Aug 14, 2026, NMRA reported earnings of -0.23 USD per share (EPS) for Q2 26, beating the estimate of -0.24 USD, resulting in a 6.05% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -7.51% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Nanobiotix S.A. - ADR
Report Date
Sep 25, 2026 For Q2 26
Estimate
-$0.11
Actual
-$0.70
Surprise
-496.76%
AnaptysBio, Inc. Common Stock
Report Date
Sep 21, 2026 For Q2 26
Estimate
$0.00
Actual
$0.07
Surprise
+2,158.06%
Inventiva S.A. - ADR
Report Date
Sep 28, 2026 For Q2 26
Estimate
-$0.37
Actual
-$0.25
Surprise
+33.55%
BlossomHill Therapeutics, Inc. Common Stock
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$1.03
Actual
-$8.75
Surprise
-746.56%
Rezolute, Inc. Common Stock (NV)
Report Date
Sep 24, 2026 For Q4 26
Estimate
-$0.15
Actual
-$0.20
Surprise
-32.45%
Abivax SA - ADR
Report Date
Sep 21, 2026 For Q2 26
Estimate
-$1.82
Actual
-$2.09
Surprise
-14.47%
AYTU BioPharma, Inc. Common Stock
Report Date
Sep 22, 2026 For Q4 26
Estimate
-$0.33
Actual
$0.00
Surprise
+99.70%
Neuphoria Therapeutics Inc. Common Stock
Report Date
Sep 18, 2026 For Q4 26
Estimate
-$0.57
Actual
-$0.95
Surprise
-66.32%
NewcelX Ltd. Ordinary Shares
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$0.54
Actual
-$0.96
Surprise
-77.58%
Palatin Technologies, Inc. Common Stock
Report Date
Sep 28, 2026 For Q4 26
Estimate
-$1.21
Actual
-$1.11
Surprise
+8.42%
FAQ
What were Neumora Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Neumora Therapeutics, Inc. Common Stock reported EPS of -$0.23, beating estimates by 6.05%, and revenue of $0.00, 0% as expectations.
How did the market react to Neumora Therapeutics, Inc. Common Stock's Q2 2026 earnings?
The stock price moved down -7.51%, changed from $1.73 before the earnings release to $1.60 the day after.
When is Neumora Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for --.
What are the forecasts for Neumora Therapeutics, Inc. Common Stock's next earnings report?
Based on --
analysts, Neumora Therapeutics, Inc. Common Stock is expected to report EPS of -- and revenue of -- for Q-- --.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.